Biotech IPO revival faces competition from cash-rich big pharma buyers
Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Biotech IPO revival faces competition from cash-rich big pharma buyers basliginda one cikan gelisme: Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.